Fresenius stock gains as Q3 strength lifts 2026 outlook
Published on 11/06/2026 at 17:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSStronger quarter lifts expectations
- Fresenius raised its full-year 2026 Core EPS growth outlook after organic third-quarter revenue growth of 5 percent.
- Group EBIT margin improved to 11.0 percent, while Core EPS rose 14 percent at constant currency.
- Fresenius Kabi and Fresenius Helios both contributed to the quarterly operating performance.
Fresenius raised its 2026 earnings and margin outlook on Wednesday, November 4, after reporting stronger operating performance for the third quarter. The update came from the company's Q3 2026 results release.
Guidance moves higher
Fresenius now expects constant-currency Core EPS growth in the upper half of its 10 percent to 15 percent range for 2026. The group EBIT margin indication was raised to above 11.5 percent from around 11.5 percent previously. The company kept its organic revenue growth outlook at 4 percent to 7 percent.
Group revenue reached 5,803 million euros in the quarter, with organic growth of 5 percent. EBIT before special items rose 10 percent in constant currency to 638 million euros, lifting the margin by 50 basis points to 11.0 percent. Core EPS increased 14 percent in constant currency to 0.72 euros.
Kabi and Helios support growth
Fresenius Kabi recorded organic revenue growth of 6 percent, led by its Growth Vectors. Biopharma growth was 29 percent, while Kabi EBIT rose 8 percent in constant currency to 391 million euros. Fresenius Helios delivered 5 percent organic revenue growth and EBIT of 293 million euros, up 19 percent in constant currency.
Management also highlighted a strategic agreement with WuXi Biologics announced on November 2. The agreement gives Fresenius exclusive access to up to 37 potential first-to-market biosimilar candidates and expands the company's development pipeline.
Share price and investor view
The real-time quote of Fresenius stock traded at 52.08 euros on Lang & Schwarz at 17:11 CET on Friday, November 6, 0.40 percent above the Xetra close of Thursday, November 5.
The combination of margin expansion, debt reduction and higher earnings visibility gives investors a stronger operating framework for assessing the stock. Fresenius said its net debt-to-EBITDA ratio stood at 2.5 times at the end of the quarter.
Fresenius stock at a glance
- Company: Fresenius SE & Co. KGaA
- ISIN: DE000FRE5EN2
- Ticker: FRE.DE
- Latest quote: 52.08 euros on Lang & Schwarz, Friday, November 6, 2026, at 17:11 CET
- Daily comparison: 0.40 percent above the Xetra close of Thursday, November 5
The German equity market remains the broader setting for investors tracking healthcare shares and earnings revisions.
More news and analyses on Fresenius stock cover further developments in the company and its outlook.
